A pioneering breakthrough in SL-based cancer therapy showed that inhibition of poly (ADP-ribose) polymerase (PARP) in cancer cells that harbour loss-of-function events in the breast-cancer susceptibility genes BRCA1 and BRCA2 is dramatically lethal to these cells [9, 10] (reviewed in [11]). This evidence concerns the gene BRCA2 and breast carcinoma.